Advertisement

Clinical Pharmacokinetics

, Volume 47, Issue 11, pp 753–764 | Cite as

Pharmacokinetics of Subcutaneous Recombinant Methionyl Human Leptin Administration in Healthy Subjects in the Fed and Fasting States

Regulation by Gender and Adiposity
  • Jean L. Chan
  • Shekman L. Wong
  • Christos S. MantzorosEmail author
Original Research Article

Abstract

Background: Recombinant methionyl human leptin (r-metHuLeptin) has demonstrated efficacy in improving hormonal and metabolic parameters in leptin-deficient states, and it has been suggested that leptin replacement may reverse metabolic adaptations during weight loss interventions. The pharmacokinetics of subcutaneously administered r-metHuLeptin have been recently published, but whether pharmacokinetic parameters are altered by short-term fasting, adiposity and/or gender has not yet been evaluated.

Objective: The objective of this study was to characterize pharmacokinetic parameters following subcutaneous r-metHuLeptin administration at doses in the physiological to supra-physiological to pharmacological range in the fed state and during 3-day complete fasting in lean and obese subjects, including both men and women.

Methods: We analysed pharmacokinetic profiles in five lean men, five obese men and five lean women following subcutaneous administration of physiological (0.01 mg/kg), supra-physiological (0.1 mg/kg) and pharmacological (0.3 mg/kg) doses of r-metHuLeptin given once in the fed state and once daily during 3-day complete caloric deprivation (fasting).

Results: With r-metHuLeptin administration at 0.01 mg/kg, leptin concentrations ranged up to ∼7 ng/mL in lean men, ∼20 ng/mL in obese men and ∼30 ng/mL in lean women in the fed state. There was a significant effect of 3-day fasting: it decreased baseline leptin concentrations, peak serum concentration (Cmax) and area under the serum concentration-time curve from time zero to infinity (AUC) [all p < 0.0001] and increased clearance (p < 0.001), most prominently in lean men (p < 0.0001 across the groups). Administration of r-metHuLeptin at 0.1 mg/kg resulted in leptin concentrations up to ∼70 ng/mL in lean men, ∼100 ng/mL in obese men and ∼150 ng/ mL in lean women in the fed state. At this dose, there was a similar effect of fasting on the pharmacokinetic parameters as well as a decrease in the terminal-phase elimination half-life (p = 0.02), consistent with increased clearance, but the effect of fasting was less pronounced overall than with the 0.01 mg/kg dose. With r-metHuLeptin administration at 0.3 mg/kg, leptin concentrations ranged up to ∼150 ng/mL in lean men, ∼300 ng/ mL in obese men and ∼400 ng/mL in lean women in the fed state. At this dose, fasting increased clearance to a lesser degree (p = 0.046), mainly in lean men, suggesting that the fasting-induced increase in leptin clearance by the kidneys can plateau. Within each group, the subjects lost ∼3–4 kg of bodyweight after 3 days of fasting (all p < 0.0001), but the amount and time course of weight loss did not differ according to the dose of r-metHuLeptin administered or the circulating leptin concentrations achieved.

Conclusions: Short-term fasting in healthy individuals results in increased clearance of leptin; this contributes to hypoleptinaemia, which may serve as a signal to increase energy intake in the setting of caloric restriction. Obese individuals with greater energy stores at baseline have a blunted response to the fasting-induced increase in leptin clearance. Also, women have a differential response to fasting, with primarily decreased leptin production rather than increased clearance. These findings and the resulting formulas for calculating doses for r-metHuLeptin administration have important implications for future therapeutic use of r-metHuLeptin in conjunction with hypocaloric diets for the treatment of obesity.

Keywords

Pramlintide Lean Woman General Clinical Research Center Fasting Study Beth Israel Deaconess Medical Center 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We gratefully thank the General Clinical Research Center (GCRC) nurses at Beth Israel Deaconess Medical Center (BIDMC) for assistance with collection of the samples for this research, and the GCRC nutritionists for assistance with the isocaloric diet and fasting studies. This study was supported by NIH grant no. M01-RR01032 to the BIDMC GCRC; NIH DK grant nos. R01-58785, R01-79929 and K24 81913 and an Amgen grant and a BIDMC discretionary grant to Christos Mantzoros; and NIH grant no. K23 RR018860 to Jean Chan. Christos Mantzoros has received honorarium for one lecture and grant support through BIDMC-Harvard from Amylin, Inc. Jean Chan and Shekman Wong have no conflicts of interest to report.

References:

  1. 1.
    Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 Dec 1; 372(6505): 425–32PubMedCrossRefGoogle Scholar
  2. 2.
    Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002 Oct; 110(8): 1093–103PubMedGoogle Scholar
  3. 3.
    Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002 Feb 21; 346(8): 570–8PubMedCrossRefGoogle Scholar
  4. 4.
    Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006 Jul; 91(7): 2605–11PubMedCrossRefGoogle Scholar
  5. 5.
    Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004 Sep 2; 351(10): 987–97PubMedCrossRefGoogle Scholar
  6. 6.
    Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999 Oct 27; 282(16): 1568–75PubMedCrossRefGoogle Scholar
  7. 7.
    Hukshorn CJ, Westerterp-Plantenga MS, Saris WH. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am J Clin Nutr 2003 Apr; 77(4): 771–6PubMedGoogle Scholar
  8. 8.
    Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008 May 20; 105(20): 7257–62PubMedCrossRefGoogle Scholar
  9. 9.
    Chan JL, Heist K, DePaoli AM, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003 May; 111(9): 1409–21PubMedGoogle Scholar
  10. 10.
    Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005 Dec; 115(12): 3579–86PubMedCrossRefGoogle Scholar
  11. 11.
    Wong SL, DePaoli AM, Lee JH, et al. Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metab 2004 Jun; 89(6): 2672–7PubMedCrossRefGoogle Scholar
  12. 12.
    Chan JL, Wong SL, Orlova C, et al. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. J Clin Endocrinol Metab 2007 Jun; 92(6): 2307–11PubMedCrossRefGoogle Scholar
  13. 13.
    Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord 1996 Dec; 20(12): 1120–6PubMedGoogle Scholar
  14. 14.
    Zeng J, Patterson BW, Klein S, et al. Whole body leptin kinetics and renal metabolism in vivo. Am J Physiol 1997 Dec; 273 (6 Pt 1): E1102–6PubMedGoogle Scholar
  15. 15.
    Meyer C, Robson D, Rackovsky N, et al. Role of the kidney in human leptin metabolism. Am J Physiol 1997 Nov; 273 (5 Pt 1): E903–7PubMedGoogle Scholar
  16. 16.
    Jensen MD, Moller N, Nair KS, et al. Regional leptin kinetics in humans. Am J Clin Nutr 1999 Jan; 69(1): 18–21PubMedGoogle Scholar
  17. 17.
    Landt M, Martin DR, Zeng J, et al. Plasma leptin concentrations are only transiently increased in nephrectomized rats. Am J Physiol 1998 Sep; 275 (3 Pt 1): E495–9PubMedGoogle Scholar
  18. 18.
    Klein S, Coppack SW, Mohamed-Ali V, et al. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996 Jul; 45(7): 984–7PubMedCrossRefGoogle Scholar
  19. 19.
    Alvero R, Kimzey L, Sebring N, et al. Effects of fasting on neuroendocrine function and follicle development in lean women. J Clin Endocrinol Metab 1998 Jan; 83(1): 76–80PubMedCrossRefGoogle Scholar
  20. 20.
    Klein S, Horowitz JF, Landt M, et al. Leptin production during early starvation in lean and obese women. Am J Physiol Endocrinol Metab 2000 Feb; 278(2): E280–4PubMedGoogle Scholar
  21. 21.
    Chan JL, Matarese G, Shetty GK, et al. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci U S A 2006 May 30; 103(22): 8481–6PubMedCrossRefGoogle Scholar
  22. 22.
    Rosenbaum M, Nicolson M, Hirsch J, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996 Sep; 81(9): 3424–7PubMedCrossRefGoogle Scholar
  23. 23.
    Elbers JM, Asscheman H, Seidell JC, et al. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab 1997 Oct; 82(10): 3267–70PubMedCrossRefGoogle Scholar
  24. 24.
    Shimizu H, Shimomura Y, Nakanishi Y, et al. Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 1997 Aug; 154(2): 285–92PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Jean L. Chan
    • 1
  • Shekman L. Wong
    • 2
  • Christos S. Mantzoros
    • 1
    Email author
  1. 1.Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA
  2. 2.Theravance, Inc.South San FranciscoUSA

Personalised recommendations